With a range of investments in recent weeks, Indian companies are on a job creation spree in the US. Mankind Pharma to enter US New Delhi-based Mankind Pharma Ltd is working to make inroads in the US market and plans to file its first set of generic products with the regulator in 2018. Rajeev Juneja, chief executive officer of Mankind Pharma, said: “We will develop innovative products for the US market. We are setting up a manufacturing plant in the US with a total investment of $30 million. We are establishing this US manufacturing organically. "The building setup is ready; however, equipment and utilities are under commissioning” He added that the company is also in the process of getting some of its Indian units approved by the US Food and Drug Administration (FDA). While the company has been successful in the domestic market, which accounts for nearly 90 per cent of its revenue, analysts believe that tapping the US market will be challenging as the company is a late entrant compared to its Indian peers and current market conditions in the US are challenging. Although the company is trying to increase its international presence, the Indian market will be its priority as it aims to be among the top three players in the country.
Lenskart invests $1mn in Ditto
India-US work on state-wise strategy
Wipro sets up California centre